Tumor necrosis factor inhibitors (TNFi) are the first class of biological DMARDs (bDMARDs) used in treating RA and AS, their anti-inflammatory effect mainly resulting from the binding of cytokines in order to block TNF-mediated signaling4. Here, TNF is linked to rheumatoid arthritis.